上海汉都医药科技

Handu Pharma is a clinical-stage biotechnology company founded in 2016 and based in Shanghai's Zhangjiang Hi-Tech Park. The company specializes in the development of innovative drug-device combination products and advanced drug delivery systems, primarily utilizing the 505(b)(2) regulatory pathway to improve existing therapies. Handu has established five core technology platforms, including gastrointestinal positioning controlled-release (U-Sert) and osmotic pump systems (G-Sert), to address unmet clinical needs in central nervous system disorders, cardiovascular diseases, and pediatric/geriatric medicine. Its lead program, HD-001, is a controlled-release formulation for Parkinson's disease currently in late-stage clinical development. The company is led by a team of industry veterans with extensive experience at the FDA and major pharmaceutical firms like Johnson & Johnson.